QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-neutral-on-molecular-partners-lowers-price-target-to-4

JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from ...

 molecular-partners-q2-eps-067-down-from-056-yoy

Molecular Partners (NASDAQ:MOLN) Q2 EPS $(0.67) Down from $(0.56) YoY

 molecular-partners-to-reduce-workforce-by-up-to-24

In H1 2025, Molecular Partners undertook a strategic review of its operations and headcount, with the objectives of increased e...

 reported-sunday-molecular-partners-and-orano-med-present-preclinical-data-on-mesothelin-targeting-radio-darpin-mp0726-at-snmmi-2025

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for...

 molecular-partners-to-cut-up-to-40-jobs-in-strategic-review-extends-cash-runway-into-2028

Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025Cash reach now anticipated to extend into 2028

 correction-molecular-partners-q1-eps-051

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.51) per share.

 molecular-partners-presents-new-preclinical-data-on-radio-darpin-and-switch-darpin-programs-at-aacr-2025-first-preclinical-data-of-novel-targeted-radio-darpin-against-mesothelin-in-co-development-with-orano-med

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, e...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION